Oxford BioMedica plc (LON:OXB) insider Martin Diggle acquired 100,000 shares of Oxford BioMedica plc stock in a transaction dated Friday, September 15th. The stock was purchased at an average cost of GBX 8 ($0.10) per share, for a total transaction of £8,000 ($10,331.91).

Martin Diggle also recently made the following trade(s):

  • On Thursday, August 31st, Martin Diggle sold 2,377,600 shares of Oxford BioMedica plc stock. The shares were sold at an average price of GBX 10 ($0.13), for a total value of £237,760 ($307,064.45).
  • On Friday, September 1st, Martin Diggle acquired 320,000 shares of Oxford BioMedica plc stock. The stock was purchased at an average cost of GBX 9 ($0.12) per share, for a total transaction of £28,800 ($37,194.89).
  • On Thursday, July 13th, Martin Diggle acquired 660,000 shares of Oxford BioMedica plc stock. The stock was purchased at an average cost of GBX 9 ($0.12) per share, for a total transaction of £59,400 ($76,714.45).

Oxford BioMedica plc (LON:OXB) traded down 2.74% on Friday, reaching GBX 7.81. The company had a trading volume of 2,638,720 shares. The stock’s market cap is GBX 241.19 million. Oxford BioMedica plc has a one year low of GBX 2.98 and a one year high of GBX 11.25. The company has a 50-day moving average of GBX 8.90 and a 200 day moving average of GBX 6.56.

ILLEGAL ACTIVITY WARNING: This piece of content was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/09/15/oxford-biomedica-plc-oxb-insider-martin-diggle-acquires-100000-shares.html.

Several equities analysts have recently weighed in on the company. N+1 Singer lifted their price objective on Oxford BioMedica plc from GBX 8.70 ($0.11) to GBX 10.20 ($0.13) and gave the company a “hold” rating in a research note on Thursday, August 31st. Jefferies Group LLC restated a “buy” rating and set a GBX 13 ($0.17) price objective on shares of Oxford BioMedica plc in a report on Thursday, August 31st. Finally, Shore Capital restated a “not rated” rating on shares of Oxford BioMedica plc in a report on Thursday, July 13th.

About Oxford BioMedica plc

Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company’s segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners.

Insider Buying and Selling by Quarter for Oxford BioMedica plc (LON:OXB)

Receive News & Ratings for Oxford BioMedica plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica plc and related companies with MarketBeat.com's FREE daily email newsletter.